HIGHLIGHTS
- who: Jian-Xu Li from the Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China have published the research work: Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study, in the Journal: (JOURNAL)
- what: This study assessed the efficacy and safety of radiotherapy (RT) plus monoclonal antibody against programmed cell death 1 (anti-PD1) versus TACE plus for patients with advanced HCC.
SUMMARY
A total of 78 patients were enrolled in this study with 37 in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.